🇺🇸 Lisaftoclax in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 14
Most-reported reactions
- Anaemia — 2 reports (14.29%)
- Cardiac Failure — 2 reports (14.29%)
- Death — 2 reports (14.29%)
- Thrombocytopenia — 2 reports (14.29%)
- Acute Myocardial Infarction — 1 report (7.14%)
- Aspartate Aminotransferase Increased — 1 report (7.14%)
- Blood Creatinine Increased — 1 report (7.14%)
- Colitis — 1 report (7.14%)
- Covid-19 — 1 report (7.14%)
- Cytopenia — 1 report (7.14%)
Other Other approved in United States
Frequently asked questions
Is Lisaftoclax approved in United States?
Lisaftoclax does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Lisaftoclax in United States?
M.D. Anderson Cancer Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.